UZAY, A. Et Al. 2024. BEGEV is an Effective Therapy for Heavily Pretreated and Platinum-Resistant Relapsed/Refractory Hodgkin's Lymphoma Patients: A Single Center Real-Life Experience. INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION .

UZAY, A., Tasci, E. S., Gundogdu, Y., Mutlu, A. U., Yetis, T., Kosan, B., ... Karti, S.(2024). BEGEV is an Effective Therapy for Heavily Pretreated and Platinum-Resistant Relapsed/Refractory Hodgkin's Lymphoma Patients: A Single Center Real-Life Experience. INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION .

UZAY, Ant Et Al. "BEGEV is an Effective Therapy for Heavily Pretreated and Platinum-Resistant Relapsed/Refractory Hodgkin's Lymphoma Patients: A Single Center Real-Life Experience," INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , 2024

UZAY, Ant Et Al. "BEGEV is an Effective Therapy for Heavily Pretreated and Platinum-Resistant Relapsed/Refractory Hodgkin's Lymphoma Patients: A Single Center Real-Life Experience." INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , 2024

UZAY, A. Et Al. (2024) . "BEGEV is an Effective Therapy for Heavily Pretreated and Platinum-Resistant Relapsed/Refractory Hodgkin's Lymphoma Patients: A Single Center Real-Life Experience." INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION .

@article{article, author={Ant UZAY Et Al. }, title={BEGEV is an Effective Therapy for Heavily Pretreated and Platinum-Resistant Relapsed/Refractory Hodgkin's Lymphoma Patients: A Single Center Real-Life Experience}, journal={INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION}, year=2024}